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ABSTRACT
Sexually transmitted infections (STIs) are among the most common notifiable health problems worldwide, 
with particularly high rates in developing countries. Men and women with multiple sexual partners at 
home or a previous history of STIs are more likely to have casual sexual exposure (CSE) while travelling. 
Over the last several decades 5% to even 50% of short-term travellers engaged in CSE during foreign 
trips. It is estimated that only 50% of travellers use condoms during casual sex abroad. Sexual contact 
with commercial sex workers is an exceptionally high-risk behaviour. The common risk factor is also young 
age. Adolescents and young adults constitute 25% of the sexually active population, but represent almost 
50% of all new acquired STIs. Many STIs are asymptomatic and therefore can be difficult to identify and 
control. The clinical manifestation of STIs can be grouped into a number of syndromes, such as genital 
ulcer or erosion, urethral or vaginal discharge, pelvic inflammatory disease. STIs are divided into curable 
infections caused by bacteria (gonorrhoea, chlamydiasis, syphilis, chancroid, lymphogranuloma venereum, 
granuloma inguinale) or protozoa (trichomoniasis) and incurable viral infections (genital herpes, genital 
warts, HIV). STIs are not only a cause of acute morbidity, but may result in complications including male 
and female infertility, ectopic pregnancy, cervical cancer, premature mortality or miscarriage. Monoga-
mous sex with a stable, uninfected partner or sexual abstinence remains the only way to avoid the risk of 
becoming infected with STIs.
(Int Marit Health 2015; 66, 4: 238–246)
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INTRODUCTION
Travel is one of the essential risk factors in the spread 
of sexually transmitted infections (STIs) [1, 2]. This is the 
time when travellers may break social norms that normally 
restrict their sexual behaviour [3]. The most predictive factor 
is travelling without a steady partner. Men and women with 
multiple sexual partners at home or a previous history of 
STIs are more likely to have casual sexual exposure (CSE) 
while travelling [4]. Over the last decades, 5% to even 50% 
of short-term travellers engaged in CSE during foreign trips. 
The risk of developing STIs may be up to 3 times higher 
in people who experience casual travel sex, especially in 
travellers who take advantage of commercial sex in vari-
ous destinations [3]. Commercial sex workers (CSWs) run 
a particularly high risk for an STI infection. Prevalence rates 
among CSWs are remarkably high in major centres around 
the world: Nairobi, 81%; Kinshasa, 35%; Bangkok, 44%; and 
Port au Prince, 69%. The median HIV prevalence rate in fe-
male prostitutes in Thailand is 15% [5]. Long-term overseas 
workers are more likely to engage in sexual activity while 
abroad than other types of travellers. The studies of Peace 
Corps volunteers and European expatriates showed that 
13% to 60% reported at least one CSE while living overseas 
[6]. Seamen and military personnel are also reported to have 
high rates of sexual contact with overseas nationals, ranging 
from 45% to 56% [7, 8]. United Kingdom and Polish troops 
deployed in the tropics show similar rates of casual sex 
with local partners [9, 10]. In the last 30 years sex tourism 
has become more popular [11]. The contribution of com-
mercial sexual relationships between tourists and hosts to 
a country’s rise in STIs has been alerted in Thailand in the 
1980s [12], and lately in Trinidad and Tobago in 2012 [13]. 
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Sex tourism is defined as an organised holiday for men 
whose main objective is sex with local women (men, chil-
dren). Nowadays, sex tourism also applies to women looking 
for sex with local men (e.g. in eastern africa). In his studies 
Bauer [14] characterised women travelling for sexual re-
lationships dividing them into two groups: the older ones 
(lonely, disillusioned, not seen as attractive at home, bored 
in current home relationships, often retired, able to return 
frequently, seeking ‘different’ kind of attention, focused on 
relaxation, thrill, free from social constraints) and younger 
(adventurous, not seen as attractive at home, bored in 
current home relationships, focused on sex, alcohol, drugs, 
free from social constraints). de Graaf et al. [15] divided 
travellers of both sexes into four groups with regard to their 
CSE overseas: the ‘unprepared’ (who are surprised when sex 
happens), the ‘fanatical’ (who must have sex to have a suc-
cessful vacation), the ‘unaffected’ (who feel that sex abroad 
is the same as sex at home), and the ‘slightly accessible’ 
(who feel that sex abroad is different and come prepared).
The risk of acquiring STIs by travellers depends on the 
number of sexual partners, the use of condoms, and the 
prevalence of STIs in other travellers and among the local 
population. It is estimated that only 50% of travellers use 
condoms during casual sex abroad [16]. Even if they use 
condoms, there may be greater risks of failure because of 
the poor quality of locally purchased products [17]. Latex 
condoms manufactured in the developed world are generally 
more effective against viral pathogens spread by semen, 
vaginal secretions, and blood than bacterial agents associ-
ated with lesions around the genitalia. The most common 
factors involved in condom breakage include inappropriate 
application, repeated or prolonged use, and anal intercourse 
[18]. The prevalence of STIs in the destination country 
is affected by the uneven distribution of STIs worldwide. 
Male sex, travelling to visit friends or relatives, not having 
a pre-travel consultation, and duration of travel less than 
30 days were independently significantly associated with 
diagnosis of an STI in multivariate analysis [19]. Many in-
ternational travellers incubating the STIs transmit their 
infections unknowingly to their sexual partners on returning 
home, while they are still asymptomatic. Hepatitis B, HIV and 
syphilis may also be transmitted by contaminated blood and 
blood products, contaminated syringes and needles used 
for injections, and potentially by unsterilised instruments 
used for acupuncture, piercing and tattooing [5]. The com-
mon risk factor of many STIs is young age. adolescents 
and young adults (15–24 years old) make up 25% of the 
sexually active population, but represent almost 50% of 
all newly acquired STIs [20]. This may be explained by the 
fact that this age group is more likely to engage in high-risk 
sexual behaviour than the older population. Other groups 
known to engage in high-risk sexual behaviour (such as sex 
with multiple partners and unprotected sex) include CSWs, 
intravenous drug users, and prison inmates. additional 
risk factors for STIs include lack of male circumcision, low 
socioeconomic status, poor hygiene, and the route of trans-
mission [21]. There is clear evidence that circumcised men 
are at a significantly lower risk of acquiring HIV infection and 
other STIs [22]. The risk of acquiring HIV, HBV, or HCV from 
a percutaneous injury is, on average, 0.5%, 4–30%, and 
3–10%, respectively [23]. The risks which may arise from 
a single, unprotected, heterosexual intercourse are thought 
to be much lower: 0.001% for HIV [24] and 0–0.6% for HCV 
[25]. The presence of genital lesions can dramatically in-
crease the risk of acquiring HIV and other STIs [26]. a single 
episode of vaginal intercourse incurs a 20% to 50% risk of 
acquiring gonorrhoea [27]. The transmission efficiencies for 
open syphilis and chancroid lesions are probably at least as 
high. Chlamydia trachomatis is transmitted heterosexually 
with only slightly lower efficiency than gonorrhoea (0.8–8%/ 
/episode) [28].
EPIDEMIOLOGY OF TRAVEL-RELATED STIs
Worldwide, international tourist arrivals have increased 
from 278 million in 1980 to 1,133 million in 2014, po-
tentially enhancing the interaction between travel and 
the spread of STIs [29]. according to the World Health 
Organisation (WHO) more than 1 million people acquire 
a sexually transmitted infection every day; more than 
530 million people are infected with Herpes simplex virus 
which causes genital herpes (HSV-2); more than 290 mil-
lion women have Human Papillomavirus (HPV), an etiologi-
cal factor for genital warts. The majority of STIs are present 
without any symptoms; some STIs may increase the risk of 
HIV acquisition 3-fold or more; drug resistance, especially 
for gonorrhoea, is a major threat to reducing the impact of 
STIs worldwide [30]. Large population-based prevalence 
surveys undertaken in some african countries have con-
firmed high prevalence of STIs, even in rural populations. 
Syphilis was found in 5% to 10% of adults, trichomoniasis 
in 20% to 30% of women and 10% of men, and bacterial 
vaginosis in up to 50% of women [31]. The impact of HIV/ 
/aIDS has been catastrophic in many developing countries; 
more than 20% of adults are infected in some parts of 
africa [32]. an estimated 500 million cases of the most 
common STIs (chlamydiasis, gonorrhoea, syphilis, tricho-
moniasis) occur in the world each year [30]. Many STIs are 
asymptomatic and therefore can be difficult to identify and 
control. Thus, the worldwide incidence of new STIs may 
be even higher. For example, it is estimated that actually 
reported cases represent only 50% to 80% of reportable 
STIs in the United States, reflecting limited screening and 
low disease reporting [20]. STIs are not only a cause of 
acute morbidity in adults, but may result in complications 
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including male and female infertility, ectopic pregnancy, 
cervical cancer, premature mortality or miscarriage [33]. 
The spectrum of STIs presumably acquired during travel 
has been found to be broad [34]. Some infections are more 
prevalent in developing countries (chancroid, lymphogran-
uloma venereum (LGV), granuloma inguinale) or in specific 
regions (treatment-resistant gonorrhoea and gonorrhoea 
with decreased susceptibility to cephalosporins in asia), 
and may be imported into other countries by travellers 
returning from such destinations [35]. Matteelli et al. [36] 
described the range of diseases and the demographic and 
geographical factors associated with the acquisition of trav-
el-related STIs through the analysis of the data gathered 
by the GeoSentinel travel medicine clinics worldwide in 
the period between June 1996 and November 2010. STIs 
were identified in three clinical settings: after travel, during 
travel, and immigration travel. In total, 112,180 ill travellers 
were seen. 974 (0.9%) patients had diagnoses of STIs, and 
1,001 STIs were diagnosed. The proportionate STI morbid-
ities were 6.6, 10.2, and 16.8 per 1,000 travellers in the 
three groups, respectively. The most common STI diagno-
ses were non-gonococcal or unspecified urethritis (30.2%), 
acute HIV infection (27.6%), and syphilis (22.2%) in patients 
seen after travel; non-gonococcal or unspecified urethri-
tis (21.1%), epididymitis (15.2%), and cervicitis (12.3%) in 
patients seen during travel (travellers visited GeoSentinel 
clinics in Kathmandu, Singapore, Beijing, Hong Kong, Ho 
Chi Minh City, and Peekshill, United States); and syphilis in 
immigrant travellers (67.8%), who visited GeoSentinel clinics 
in western Europe, Canada, United States, and australia. In 
ill travellers seen after travel, significant associations were 
noted between diagnosis of STIs and male sex, travelling 
to visit friends or relatives, travel duration of less than 
1 month, and not having pre-travel health consultations. The 
high frequency of epididymitis, cervicitis, and acute pelvic 
inflammatory disease (PID) in travellers seen during travel 
suggests that STI-related acute complications in the uro-
genital tract might be an underestimated risk in travellers. 
STIs can be divided into curable infections caused by 
bacteria (gonorrhoea, chlamydiasis, syphilis, chancroid, 
LGV, granuloma inguinale) or protozoa (trichomoniasis) and 
incurable viral infections (genital herpes, genital warts, HIV) 
that are often of lifelong duration [21, 32]. The epidemiology 
of the most common travel-related STIs (excluding HBV and 
HCV infections) is discussed below.
Gonorrhoea. Estimated prevalence rates for gonorrhoea 
range from 5.7% to 17% in sub-Saharan africa and 0.1% to 
3.5% in asia and Western Pacific countries. although the 
number of reported cases increased in some European 
countries during the 1990s, the overall incidence of gon-
orrhoea urethritis in the developed world remains at quite 
a low level (2.5–125 per 100,000) [37]. Gonorrhoea is more 
likely to be transmitted from asymptomatic carriers than 
from symptomatic ones. Over 62 million people become 
infected worldwide annually [38]. Centres for Disease Con-
trol and Prevention estimate that only 50% of gonorrhoeal 
infections are actually reported since the disease often 
presents with few or no symptoms. 50% of women contract 
gonorrhoea after a single exposure with infected males and 
20% of men contract infection after a single sexual contact 
with infected females [39].
Chlamydiasis. Chlamydia trachomatis is responsible for 
more cases of STIs than any other bacterial pathogen. Since 
asymptomatic infection is common, it can easily be passed 
unknowingly between sexual partners. The WHO estimates 
that over 90 million new cases of chlamydia are diagnosed 
each year [40]. Worldwide, prevalence rates are similar to 
those reported in the United States, ranging between 5% 
and 15% [41, 42]. Prevalence rates for chlamydia infection 
in family planning clinics range from 1.9% to 12.2% in Latin 
america, 6% to 13% in african countries, and 5.7% to 26% 
in South/Southeast asia [37]. The highest rates have been 
consistently found among young sexually active women, 
particularly adolescents [43]. Prevalence among females 
appears to be up to three or four times higher than in 
males. This may be due to anatomical factors, as the cervix 
of adolescent females is not sufficiently developed and is 
therefore particularly susceptible to STIs [44]. Worldwide, 
the greatest number of chlamydia infections were detect-
ed among individuals of the black Caribbean race [40]. 
High prevalence of chlamydia was also observed among 
female sex workers in Central africa (38.3%). Chlamydia is 
associated with increased susceptibility to other STIs and 
transmission of HIV infection as well [45].
Syphilis. The prevalence of syphilis decreased to low 
levels in high-resource settings over the last decades, main-
ly as a consequence of an expanded coverage of health 
systems and the availability of effective diagnostic and 
treatment tools. In this scenario, individuals who acquire 
the infection during international travel have the potential to 
act as infectious foci and start epidemic outbreaks [46]. In 
most developed countries, syphilis incidence rates remained 
well below 5 per 100,000 through the 1990s. In contrast, 
there has been a striking increase in the reported rates of 
new syphilis cases during this period in Eastern Europe, in 
Russia and Ukraine (120–170 per 100,000). The reported 
seroprevalence of syphilis is generally higher in developing 
countries ranging from 3.5–8% in South/Southeast asia 
and the Western Pacific, 5–6% in Latin america, and to 
2.5–17% in sub-Saharan africa [37]. 
Chancroid. This bacterial STI is endemic in many de-
veloping and resource-poor countries. Most infections are 
clinically apparent (few asymptomatic carriers). Chancroid 
is easily spread; it is estimated that the risk of transmission 
www.intmarhealth.pl 241
Krzysztof Korzeniewski, Dariusz Juszczak, Travel-related sexually transmitted infections
 
from an infected to an uninfected person during a sin-
gle sexual exposure is between 35% and 70%. Worldwide 
estimates range between 6 and 7 million new cases of 
illness each year. However, due to the lack of availability 
of diagnostic tests, these numbers are often approximate. 
The prevalence of chancroid in cases of genital ulcerative 
disease ranged between 23% and 56% in endemic areas 
of asia, africa, and the Caribbean. This compares to approx. 
1% of the ulcers from STI clinics in European countries [47]. 
Lymphogranuloma venereum. The epidemiology of LGV 
is not well-defined owing to the lack of sensitive and specific 
diagnostic tests. The classical form of LGV is largely confined 
to the tropics, where in most places it accounts for only 
a small proportion of patients with STIs. The disease is seen 
more often in men than women. Since 2004, there has 
been a dramatic rise in LGV presenting with proctitis among 
homosexual HIV-positive males in Europe [48].
Granuloma inguinale. Prior to the antibiotic era, gran-
uloma inguinale (donovanosis) was prevalent worldwide, 
nowadays, however, significant numbers are found only in 
a few developing countries, with the main foci being Papua 
New Guinea, Zimbabwe, parts of Republic of South africa, 
India and Brazil, and among the aboriginal population of 
australia [49, 50]. 
Trichomoniasis. The WHO estimates an incidence of 
170–190 million new cases of Trichomonas vaginalis in-
fection worldwide each year. an estimated 7.4 million new 
cases of T. vaginalis infection are reported every year in 
the United States. Prevalence ranges between 2.2% for 
young women (< 20 years) compared with 6.1% in women 
> 25 years. Male prevalence is lower for both age cate-
gories (0.8% among men < 20 years and 2.8% in males 
> 25 years) [51]. among pregnant women in tropical coun-
tries trichomoniasis prevalence rates ranged from 2.1% in 
Brazil [52] to 9.9% in the Central african Republic [53], and 
41.4% in South africa [54]. Trichomoniasis is frequently 
asymptomatic in men, or may cause a short-lived course of 
nongonococcal urethritis. Women infected with T. vaginalis 
may also be asymptomatic (up to 30% of cases), but the 
majority experience vaginitis [51].
Genital herpes. The prevalence of HSV-2 seropositivity 
varies widely with generally higher rates in developing coun-
tries (from 2% to 74% according to the country, age, gender, 
and urban vs. rural areas). In sub-Saharan africa, 30–80% of 
women and 10–50% of men were found to be seropositive 
for HSV-2. Central and South america had rates from 20% 
to 40% [55]. a population-based study in rural Tanzania 
found that 50% of women and 25% of men were infected 
with HSV-2 by the age of 20 [56]. a very high prevalence 
of HSV-2 infection has been found in several other african 
countries [57]. The proportion of genital ulcers caused by 
HSV-2 has increased greatly in populations with a high HIV 
prevalence. In the United States, the overall prevalence of 
genital herpes is higher in women (25.6%) compared with 
men (17.8%) and in blacks (45.9%) compared to non-His-
panic whites (17.6%) [58]. 
Genital warts. at present, HPV infections are commonly 
diagnosed viral STI worldwide. It is estimated that around 
290 million women are infected with HPV. africa had the 
highest (31.6%), while Southeast asia (6.2%) and southern 
Europe (6.8%) the lowest estimated HPV prevalence [59]. 
The prevalence of HPV infections is believed to be lower 
in men than in women. Circumcision is an independent 
protective factor in men. HPV is recognised as a causal 
agent in the pathogenesis of cervical cancer, the second 
most common malignancy in women, representing 9.8% of 
all female cancers [60]. 
HIV/AIDS. The WHO estimates that 70 million people 
have been infected with HIV since the start of the epidemic, 
35 million of whom have died. 35.3 million people were 
living with HIV (two-thirds of them in sub-Saharan africa), 
and 1.6 million people died of aIDS-related conditions 
in 2012 [61]. The highest prevalence of HIV is in Botswana, 
Lesotho, Swaziland, Zimbabwe and the Republic of South 
africa. according to the UNaIDS statistics, the highest num-
ber of HIV infected is reported in Republic of South africa 
(5.5 million people). The second highest prevalence of HIV in-
fections is seen in Southeast and South asia, India alone has 
5.2 million inhabitants infected HIV. Currently, there has 
been a surge in newly reported HIV infections and aIDS cas-
es in the post-Soviet countries. In Russia, HIV prevalence has 
been estimated at 2% of the country’s population (UNaIDS 
estimates that there are 500,000 people living with HIV in the 
Moscow metropolitan area alone). The World Bank analyses 
show that there will have been approx. Five million HIV-in-
fected individuals in Russia by 2020. The HIV prevalence in 
Ukraine is probably 1.5% of the country’s population [62].
CLINICAL SYMPTOMS  
OF TRAVEL-RELATED STIs
The clinical manifestation of STIs can be grouped into 
a number of syndromes, such as genital ulcer or erosion, 
urethral or vaginal discharge, PID. However, many infections 
are asymptomatic in the early stages and the infection 
can be transmitted during this period without knowing it. 
STIs can lead to a variety of acute and chronic illnesses, 
such as infertility or ectopic pregnancy, genital ulcerations 
and mutilation, urethritis followed by urethral strictures, 
genital cancer caused by HPV, and premature death from 
HIV infection [63]. More than 20 different infectious agents 
can be acquired and/or spread by various types of sexual 
contact (e.g. vaginal sex, anal sex, oral-genital/oral-anal 
contact) [64]. The correct diagnosis of an STI is based 
on the clinical symptoms and suitably selected laboratory 
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tests. Examination of genital skin lesions (ulcer, erosion) 
should be supported by serologic tests for syphilis and 
a polymerase chain reaction (PCR) testing for genital herpes. 
If exposure occurred in areas where chancroid is common 
(africa, asia, Latin america), a test for Haemophilus ducreyi 
should be performed. Lymphadenopathy can accompany 
genital ulceration with chancroid infections, as well as with 
LGV and granuloma inguinale. If painful perianal or mucosal 
ulcers are detected, presumptive therapy should include 
a regimen for anogenital herpes. LGV should be suspect-
ed in a traveller with tender unilateral inguinal or femoral 
lymphadenopathy or proctocolitis. Testing specimens from 
the anatomic site of exposure with a PCR technique can 
detect Chlamydia trachomatis and Neisseria gonorrhoea. 
anyone who is diagnosed with an STI should be screened for 
a HIV infection. The incubation period of STIs is important for 
the diagnostic purposes. For HIV, it is accepted practice to 
conduct a control antibody test 3 months after exposure, but 
some individuals take longer to seroconvert, and therefore 
a second test should be performed after 6 months. In the 
case of syphilis, it can take some time after disappearance 
of the primary chancre, which may go totally unnoticed, 
before the basic screening tests (VDRL) turn positive. There-
fore, it is mandatory to conduct a control examination at 
least 3 months after exposure. To prevent transmission 
during the period before seroconversion, safe sexual prac-
tices, foremost through condom use, need to be proposed 
[65]. The clinical symptoms of the common travel-related 
STIs are presented below.
Gonorrhoea. In females, the illness is frequently as-
ymptomatic, often misdiagnosed as bladder or vaginal 
infection. Males experience epididymitis, urethritis, and 
penile discharge [66]. Typically men develop symptoms after 
a 2–5-day incubation period, with 90% of symptomatic infec-
tions manifesting within 14 days. asymptomatic infections 
in women (up to 80% of cases) are detected in contacts of 
symptomatic partners. Symptomatic uncomplicated infec-
tions in males typically manifest as a thick, yellow urethral 
discharge. In symptomatic females, vaginal discharge or 
dysuria are the major symptoms. accompanying symptoms 
include a variable degree of meatal itching, burning, dysuria, 
pollakiuria. Infections of the pharynx and rectum (mostly 
asymptomatic) can result from orogenital and genito-anal 
sexual contact. In females the rectum is easily infected by 
contamination from an infected vaginal discharge, common 
are also local infections of the Skene’s and Bartholin’s 
glands. Further spread of infection in women may lead to 
acute salpingitis, abscess formation or long-term problems 
of chronic PID, and increased risk of ectopic pregnancy [67].
Chlamydiasis. The incubation period of infection may 
range from days to months (usually 1–3 weeks). In males, 
chlamydial infection causes urethritis and, in a proportion of 
cases, epididymo-orchitis. In females, chlamydial cervicitis 
is often asymptomatic. Sometimes patients will complain 
of vaginal discharge, and the finding of a mucopurulent 
discharge at the cervical os is suggestive of chlamydial or 
gonococcal cervicitis. ascending infection of the female 
genital tract may lead to endometritis, salpingitis or PID. 
Because the symptoms of chlamydial PID are often mild, 
patients may present only when the sequelae of irreversible 
damage to the Fallopian tubes, leading to infertility, ectopic 
pregnancy, become apparent [67].
Syphilis. after an incubation period of 10–70 days 
(range 3–90 days), a primary chancre develops at the site 
of inoculation (primary syphilis). The chancre is typically 
painless, indurated, with a clean base and a raised edge, 
and does not bleed on contact. There is usually only a sin-
gle lesion; in males it is most commonly on the glans, the 
foreskin, the coronal sulcus or the shaft of the penis, and 
in the female on the cervix or vulva. The primary chancre 
is often accompanied by inguinal lymphadenopathy; the 
glands are characteristically hard and painless. Secondary 
syphilis presents with an array of dermatological lesions and 
eruptions that can occur 4–10 weeks after exposure. Other 
symptoms include fever, meningismus, myalgias, weight 
loss, anorexia, hair loss, arthralgias, mucous patches, and 
condylomata lata. The tertiary stage involves other organ 
systems and may lead to devastating cardiovascular and 
neurological complications [68]. Notable variations in the 
clinical expression of syphilis have been described in pa-
tients co-infected with HIV. These include multiple primary 
chancres, overlap of primary and secondary phases and 
early development of gummatous lesions [67].
Chancroid. after an incubation period of 3–7 days (range 
1–35 days), a papule appears at the site of inoculation 
which soon ulcerates. The typical ulcer of chancroid is 
painful and soft, has a purulent base with an undermined 
edge, and bleeds on contact. Multiple ulcers are commonly 
present, and there is painful inguinal lymphadenopathy in 
50% of cases, often unilateral. atypical presentations are 
common, which makes chancroid difficult to reliably distin-
guish from primary syphilis on clinical grounds. Chancroid 
may cause extensive local destruction, particularly in HIV-in-
fected individuals who may fail to respond to antimicrobial 
treatment [67].  
Lymphogranuloma venereum. The initial manifestation, 
occurring 10–14 days (range 3–21 days) after exposure, is 
typically a small, painless, usually herpetiform ulcer of the 
genitalia, which may pass unrecognised and resolve spon-
taneously. It is thought likely that some patients develop 
asymptomatic infections of the urethra and cervix. The sec-
ond phase of the illness is the development of increasingly 
painful lymphangitis and lymphadenitis, accompanied by 
fever and malaise. The infected nodes (bilateral in a third 
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of cases) coalesce into a matted mass which may project 
outwards below or above the inguinal ligament to give the 
classical ‘groove sign’. The nodes are liable to rupture, 
forming multiple sinuses. Untreated, the disease may cause 
extensive lymphatic damage, resulting in elephantiasis of 
the genitalia. In women and homosexual men, the disease 
may present as an acute proctocolitis, which leads to ab-
scess formation, fibrosis, fistula and rectal stricture [67].
Granuloma inguinale. The first manifestation, appear-
ing after a 3–40-day incubation period, is usually a small 
papule, which ruptures to form a granulomatous, painless 
lesion, bleeding readily on contact and often elevated above 
the level of the surrounding skin. The lesion has to be dif-
ferentiated from other forms of genital ulcer. Untreated, the 
ulcers slowly extend, particularly along skin-folds towards 
the groins and anus. Special features are extragenital le-
sions (mostly neck and mouth); cervical lesions (resembling 
carcinoma or tuberculous cervicitis); involvement of uterus; 
tubes and ovaries (hard masses, abscesses, ‘frozen pelvis’, 
hydronephrosis) [67]. Granuloma inguinale usually affects 
the genital (90% of cases) or inguinal region (10%). There 
are four classic presentations of the disease: ulcerogranu-
lomatous, hypertrophic or verrucous ulcers, necrotic deep 
ulcers, and cicatricial lesions [69]. 
Trichomoniasis. Incubation period of infection lasts 
5–28 days. Up to 75% of infected women complain of vag-
inal, profuse yellow-green frothy discharge. Pruritus vulvae, 
dyspareunia and dysuria are also common symptoms. The 
vulva and vaginal walls may be excoriated and erythem-
atous in severe cases, and punctate haemorrhages may 
be seen on the cervix. In men yellow urethral discharge is 
observed [67].
Genital herpes. The clinical picture is highly character-
istic (in the absence of immune suppression), with its local-
ised clusters of vesicles, which break down to form ulcers, 
crust over and then resolve. Sites of involvement include 
the external genitalia, neighbouring skin, the urethra and 
cervix, pharynx and rectum. Tender lymphadenopathy may 
occur. The complications of genital herpes include a sacral 
radiculomyelopathy which may manifest with constipation 
and retention of urine as well as shooting pains down the 
legs. Other complications include aseptic meningitis, ex-
tragenital lesions and disseminated herpes. In pregnant 
women, recurrences and dissemination are more frequent 
and premature delivery may complicate primary attacks. 
Severe and intractable ulceration due to HSV-2 occurs in 
patients immunosuppressed by HIV [67].
Genital warts. The genital, painless lesions induced by 
HPV vary from the soft, fleshy, vascular condylomata acum-
inata to papular warts. In pregnancy, in immunosuppressed 
patients and in the presence of genital discharge, there is 
a tendency for warts to grow rapidly [67]. Viral transmission 
may occur even in the absence of visible lesions and many 
patients may be unaware that they are infected. The infection 
may be obvious clinically or completely asymptomatic [70]. 
HIV/AIDS. The most common routes of HIV trans-
mission include (an estimated number of infections per 
10,000 exposures is given inside the brackets): blood 
and blood products transfusion (9,000); the use of con-
taminated needles or syringes (67); direct contact with 
contaminated blood in work settings, e.g. a health care 
worker pricked by a needle (30); transplacental mother-
to-child transmission (2,500); sexual intercourse — homo-
sexual, bisexual or heterosexual sexual contacts (without 
the use of condoms): receptive anal intercourse (50), in-
sertive anal intercourse (6.5), vaginal intercourse — 
a female (10), vaginal intercourse — a male (5), oral sex — 
the performing person (1), oral sex — the receptive person 
(0.5); other routes of transmission: infected human milk 
(breastfeeding), artificial insemination (semen from infect-
ed men), organ transplants. HIV infection may first present 
with flu-like symptoms several weeks after exposure. This 
is followed by an asymptomatic period ranging between 
several and nearly 20 years depending on the immune 
response of an infected individual. as the impairment 
progresses, CD4 lymphocyte levels are reduced while HIV 
viruses multiply and eventually the disease becomes fully 
symptomatic. In 1992, Centres for Disease Control and 
Prevention classified symptoms associated with HIV/aIDS 
(the classification has been valid since 1993). The classi-
fication system involves both clinical (a, B and C) as well 
as immunological criteria. In Europe the diagnostic criteria 
for identifying aIDS include only conditions listed in the 
clinical category C (stages C1, C2, C3), i.e. the occurrence 
of infections indicative of aIDS. In the Unites States, aIDS 
is also identified based on the immune-response criteria 
(CD4 + lymphocyte count < 200/mm3) regardless of clinical 
symptoms [62]. The opportunistic infections in aIDS-infect-
ed people include bacterial, protozoal, fungal, and viral 
diseases in addition to HIV-associated malignancies. Per-
sistent generalised lymphadenopathy occurs in Stage C1. 
Weight loss, respiratory tract infections, herpes zoster, oral 
ulcerations, and pruritic eruptions are evident in Stage C2. 
Severe weight loss, chronic diarrhoea, persistent fever, oral 
candidiasis, tuberculosis, and oral hairy leucoplakia occur in 
Stage C3. Pneumonia, empyema, meningitis, acute necro-
tising stomatitis, and bacteraemia are also characteristic in 
this stage. The progression from HIV to aIDS is associated 
with chronic herpes simplex infection, Kaposi sarcoma, cen-
tral nervous system toxoplasmosis, disseminated mycosis, 
recurrent septicaemia, and nephropathy [71]. The fungal 
infection Pneumocystis jiroveci that causes pneumonia is 
the most prevalent opportunistic infection in persons with 
aIDS and the leading cause of death [72].
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SUMMARY
In the last decades, population mobility has increased 
dramatically. More than 1 billion people crossed interna-
tional borders for work, study, or pleasure. Most of mobile 
population are sexually active people who are at increased 
risk of acquiring STIs [73]. The anonymity of travel, the sense 
of isolation brought on by unfamiliar surroundings, and 
the desire for unique experiences may encourage sexual 
activity [74]. STIs are among the most common notifiable 
infections worldwide, and rates are particularly high in de-
veloping countries. Surveys of CSW in the developing world 
reveal high rates of the curable, bacterial STIs: 13–32% for 
chlamydia, 11–45% for gonorrhoea, and 5–55% for syphilis 
[75]. When prevalence rates for the non-curable viral infec-
tions are included (HIV, HSV, HPV), the risk of exposure to 
an STI through sexual contact with a CSW is much higher. 
It is certainly worth noting that the presence of one or more 
STIs can increase the risk of HIV transmission by 3–10 times 
[37]. Prevention is the best way to decrease the morbidity 
and mortality associated with STIs. Consistent and proper 
use of latex condoms during sexual activity has a protective 
efficacy of 40–70% against STIs and should be strongly ad-
vised by doctors in travel clinics [63]. Male travellers should 
always use a condom during sexual intercourse, each time, 
from start to finish, and female travellers should make sure 
that their partners use one [3]. Some spermicides, such as 
nonoxynol-9, which interfere with sperm viability and have 
shown in vitro inhibitory activity against N. gonorrhoeae, 
HSV and HIV in STIs prevention can be useful [63]. It is 
necessary to remember, that barrier contraceptives can 
provide a protection against many STIs, but 100% protection 
cannot be achieved even when they are carefully used. Only 
HBV and HPV genotypes (hepatitis B and genital warts) can 
currently be prevented by vaccination [76]. Rates of reported 
CSE during travel vary between 5% and 51% [3]. Recent 
studies demonstrated that male and female travellers are 
quite similar in their willingness to acquire new partners 
while abroad. However, both quantitative and qualitative 
behavioural differences persist between the sexes (e.g. 
number of partners, willingness to pay for sex, consistent 
condom use, and partner choice) [77]. The common risk 
factors for engaging in casual sex while travelling include 
young age, travelling alone or with the same-sex group, 
a history of casual sex or multiple partners at home, repeat-
ed visits to the same region, history of previous STIs, higher 
social status, longer duration of stay, usage of alcohol or 
illicit drugs [78]. The effects of sun, stimulants, and sex has 
been described as ‘situational disinhibition’ [79]. Screening 
for STIs is a recommended procedure for travellers who 
report CSE while abroad [80]. Such screening should be 
guided by the nature of the sexual contact and current or 
past symptoms and could include an examination of the 
genitals, a cervical/urethral/anal/pharyngeal swab and/ 
/or urine testing, and serologic tests for syphilis, HIV, and 
possibly HBV and HCV [4]. Monogamous sex with a stable, 
uninfected partner or sexual abstinence remains the only 
way to avoid the risk of becoming infected with STIs.
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